To the editor: In contemporary patients with polycythemia vera, rates of thrombosis and risk factors delineate a new clinical epidemiology

Blood

Volumn 124, Issue 19, 2014, Pages 3021-3023

  Barbui, Tiziano ^a   Carobbio, Alessandra ^a   Rumi, Elisa ^b   Finazzi, Guido ^a   Gisslinger, Heinz ^c   Rodeghiero, Francesco ^d   Randi, Maria Luigia ^e   Rambaldi, Alessandro ^a   Gisslinger, Bettina ^c   Pieri, Lisa ^f   Bertozzi, Irene ^e   Casetti, Ilaria ^b   Pardanani, Animesh ^g   Passamonti, Francesco ^h   Vannucchi, Alessandro M ^f   Tefferi, Ayalew ^g  

^a PAPA GIOVANNI XXIII HOSPITAL   (Italy)

^b UNIVERSITY OF PAVIA   (Italy)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d SAN BORTOLO HOSPITAL   (Italy)

^e UNIVERSITY OF PADOVA   (Italy)

^f UNIVERSITY OF FLORENCE   (Italy)

^g MAYO CLINIC   (United States)

^h OSPEDALE DI CIRCOLO   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ARTERY THROMBOSIS; BONE MARROW; CARDIOVASCULAR RISK; DIABETES MELLITUS; EPIDEMIOLOGY; FOLLOW UP; HUMAN; HYPERTENSION; LETTER; MORPHOLOGY; POLYCYTHEMIA VERA; RECURRENT DISEASE; RETROSPECTIVE STUDY; RISK FACTOR; THROMBOSIS; TOBACCO USE; VEIN THROMBOSIS; WORLD HEALTH ORGANIZATION; ADOLESCENT; ADULT; AGED; FEMALE; MALE; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; POLYCYTHEMIA VERA; RETROSPECTIVE STUDIES; RISK FACTORS; THROMBOSIS; YOUNG ADULT;

EID: 84909595184     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2014-07-591610     Document Type: Letter

References (7)

1. Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia. 2013;27(9):1874-1881. 10.1038/leu.2013.163.
2. Marchioli R, Finazzi G, Specchia G, et al; CYTO-PV Collaborative Group. Cardiovascular events and intensity of treatment in polycythemia vera. N Engl J Med. 2013;368(1):22-33. 10.1056/NEJMoa1208500.
3. Landolfi R, Marchioli R, Kutti J, et al; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low-dose aspirin in polycythemia vera. N Engl J Med. 2004;350(2):114-124. 10.1056/NEJMoa035572.
4. Marchioli R, Finazzi G, Landolfi R, et al. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol. 2005;23(10):2224-2232. 10.1200/JCO.2005.07.062.
5. Vardiman JW, Thiele J, Arber DA, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-951. 10.1182/blood-2009-03-209262.
6. Sørensen HT, Horvath-Puho E, Søgaard KK, et al. Arterial cardiovascular events, statins, low-dose aspirin and subsequent risk of venous thromboembolism: a population-based case-control study. J Thromb Haemost. 2009;7(4):521-528.
7. Berk PD, Wasserman LR, Fruchtman SM, Goldberg JD. Treatment of polycythemia vera: A summary of clinical trials conducted by the polycythemia vera study group. In: Wasserman LR, Berk PD, Berlin NI, eds. Polycythemia Vera and the Myeloproliferative Disorders. Philadelphia, PA: W. B. Saunders; 1995:166-194.